RIPK3 inhibitor 18   Click here for help

GtoPdb Ligand ID: 10389

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 18 is a type II DFG-out RIPK3 inhibitor [2]. It was identified by a team in Bristol-Myers Squibb Research & Development laboratories.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 101.8
Molecular weight 512.19
XLogP 4.85
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(C1CC1)Nc1nccc(c1)Oc1ccc(c(c1C)C)NC(=O)c1cccn(c1=O)c1ccc(cc1)F
Isomeric SMILES O=C(C1CC1)Nc1nccc(c1)Oc1ccc(c(c1C)C)NC(=O)c1cccn(c1=O)c1ccc(cc1)F
InChI InChI=1S/C29H25FN4O4/c1-17-18(2)25(38-22-13-14-31-26(16-22)33-27(35)19-5-6-19)12-11-24(17)32-28(36)23-4-3-15-34(29(23)37)21-9-7-20(30)8-10-21/h3-4,7-16,19H,5-6H2,1-2H3,(H,32,36)(H,31,33,35)
1. Bryan MC, Rajapaksa NS. (2018)
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.
J Med Chem, 61 (20): 9030-9058. [PMID:29870256]
2. Hart AC, Abell L, Guo J, Mertzman ME, Padmanabha R, Macor JE, Chaudhry C, Lu H, O'Malley K, Shaw PJ et al.. (2019)
Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.
ACS Med Chem Lett, Article ASAP. DOI: 10.1021/acsmedchemlett.9b00065
3. Yan B, Liu L, Huang S, Ren Y, Wang H, Yao Z, Li L, Chen S, Wang X, Zhang Z. (2017)
Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.
Chem Commun (Camb.), 53 (26): 3637-3640. [PMID:28267172]